Sentences with phrase «tissue plasminogen activator»

To compare the safety and efficacy of tissue plasminogen activator (TPA) administered in controlled clinical trials to that of TPA prescribed in routine clinical practice.

The U.S. FDA has approved the clot - busting drug tissue plasminogen activator, or tPA, to be given within three hours of symptom onset, while the American Heart Association / American Stroke Association suggest it can be given up to 4.5 hours in some patients.

In a related editorial, Tiffany Cossey, M.D., and Nicole R. Gonzales, M.D., of The University of Texas Health Science Center at Houston, write: «Although sICH may be an uncommon occurrence, the known risk weighs heavily on the decision of clinicians to administer tPA [intravenous tissue plasminogen activator], as well as on the decisions of patients and families regarding treatment.

Intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) can improve outcomes for patients with ischemic stroke treated within 4 1/2 hours of the onset of symptoms.

Once there, they break apart into individual particles that stick to the clot, releasing a drug called tissue plasminogen activator (tPA) that dissolves it.

The patient received tissue Plasminogen Activator, a clot - dissolving drug, and improved clinically.

Researchers report that only 10 percent of frostbitten toes and fingers had to be amputated in patients who were given tissue plasminogen activator (tPA), an anti-clotting agent, in addition to standard frostbite treatment (rewarming, rehydrating and cleaning the wounded areas); in contrast, 41 percent of frostbitten digits had to be amputated in victims who received only conventional care.

N - terminal signal sequence of gp replaced by that of tissue plasminogen activator (tpa)- cleaved from

Studies show that patients who receive endovascular rescue therapy after intravenous tissue plasminogen activator (IV tPA) have better outcomes than patients treated with medical therapy alone.

If given quickly enough, recombinant tissue plasminogen activator (rtPA) can in some cases dissolve the clot, restore blood flow and minimize damage.

The only approved drug for stroke in the United States is an injectable medication called tissue plasminogen activator, or tPA.

He arrived too late to receive tissue plasminogen activator (tPA), the only treatment for ischemic strokes.

The clot - busting drug tissue plasminogen activator (tPA) to treat ischemic stroke, should be given within 4.5 hours of symptom onset.

Right now, the only widely available treatment for preventing brain damage from stroke is tissue plasminogen activator (tPA), which breaks up blood clots; it must be given within a few hours to be effective, and though it limits initial damage, it doesn't help the brain restore lost synapses or form new ones.

While the clot - busting drug known as tPA (tissue plasminogen activator) had been the only medical therapy approved for treatment of acute stroke in the United States (U.S.), the projected U.K. cost savings of mechanical thrombectomy treatment as reported in the study could correlate to the U.S., making the treatment an even better option.

Intravenous tissue plasminogen activator (tPA; an enzyme that helps dissolve clots) reduces long - term disability when administered early to eligible patients with acute ischemic stroke.

There is only one approved treatment — tissue plasminogen activator — but it is most effective when administered within 90 minutes after the onset of stroke.

Veress tested a clot - busting drug, tissue plasminogen activator (tPA), in rats exposed to normally lethal mustard doses — they all survived.

Tissue plasminogen activator (tPA) is a drug commonly used by surgeons to bust open blood clots in a patient's bloodstream, but it does have its limitations.

These standards relate to stroke rehabilitation & education, dysphagia screening, assessment of functional communication measures, use of antithrombotic agents, statin drugs, and tissue plasminogen activator, and management of transient ischemic attacks and migraine, and other related topics.

He spent the early part of his career focused on commercial activities, including contributing to the successful launches of Activase ®, a recombinant tissue plasminogen activator (rtPA), and Nutropin ® human growth hormone (hGH) while working at Genentech.

His pioneering work in the fields of gene cloning and expression of human proteins was the basis for five marketed therapeutics developed by Genentech, including human insulin, human growth hormone, interferon - alpha, interferon - gamma, and tissue plasminogen activator.

His pioneering work in the fields of gene cloning and expression of human proteins has been the basis for five significant marketed therapeutics developed by Genentech, including human insulin, human growth hormone, interferon - alpha, interferon - gamma and tissue plasminogen activator.

The only FDA - approved stroke treatment is TPA (tissue plasminogen activator), which is effective only in approximately 20 % of cases.

T - PAs (tissue plasminogen activators) like urokinase (the drug), are only effective when taken intravenously and often fail simply because a stroke or heart attack victim's arteries have hardened beyond the point where they can be treated by any other clot - dissolving agent.